Ajanta Pharma Ltd (AJANTPHARM) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Ajanta Pharma delivered strong performance in FY2025, with overall business growth of 10% despite challenges in Africa Institution business and soft US generic growth.
- Branded generics, contributing 74% of overall revenue, grew by 15% and showed sustained strength.
- Asia business expanded its product portfolio with 25 new launches, primarily in chronic therapies, achieving 13% growth.
- Africa branded generics business saw remarkable growth of 28% due to a focus on chronic therapies and 13 new product launches.
- US generics grew by 9%, with all five new product launches in the second half, positioning for stronger growth in FY2026 with a robust pipeline.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.